American Kidney Fund Announces Honorees for November 1 ‘A Pairing for Prevention’ Event in New York
FOR IMMEDIATE RELEASE
Event will raise funds to support patient-focused programs and services of the American Kidney Fund
MELVILLE, New York (October 19, 2016) – The American Kidney Fund (AKF), the nation’s largest nonprofit organization serving people with, and at risk for, kidney disease, will honor a local nephrologist and a biopharmaceutical company at its regional fundraising event, “A Pairing for Prevention,” to be held Nov. 1, 2016 at Terrace on the Park in Queens, New York.
“The community that cares for people with kidney disease knows how devastating this condition can be physically, emotionally and financially,” said LaVarne A. Burton, president and chief executive officer of the American Kidney Fund. “The support of the New York region for our programs and services helps to ensure that we can fulfill our mission of helping people fight kidney disease and live healthier lives.”
The corporate honoree, Retrophin, is dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The company’s work in kidney disease centers on cystinuria, a rare and chronic genetic disorder characterized by the formation of cystine kidney stones, and focal segmental glomerulosclerosis, a rare condition characterized by progressive scarring of the kidney that often leads to end-stage renal disease.
“We are honored to be recognized by the American Kidney Fund, and stand alongside the organization in its efforts to serve the community of patients impacted by kidney disease,” said Stephen Aselage, CEO of Retrophin. “As a company that is dedicated to developing new treatments and broadening access to our approved medications, we share in AKF’s mission to ensure that kidney patients receive the care they need.”
David S. Goldfarb, M.D. will also be honored at the event as the area’s “Nephrologist of the Year.” Dr. Goldfarb is chief of nephrology at the Department of Veterans Affairs New York Harbor Healthcare System, clinical chief of nephrology at NYU Langone Medical Center, and professor of medicine and physiology at NYU School of Medicine. In his efforts to care for others, Dr. Goldfarb complements his vast medical expertise by drawing upon his own experiences as a patient who has had kidney stones.
All funds raised at “A Pairing for Prevention” will support the mission of AKF, ensuring that every kidney patient has access to health care, and that every person at risk for kidney disease is empowered to prevent it. Now celebrating its 45th anniversary, AKF has helped more than 1 million low-income dialysis patients access lifesaving medical care.
To learn more, or to purchase tickets, please visit the event webpage or contact AKF’s Northeast Regional Office at (516) 513-5247.
About the American Kidney Fund
As the nation’s leading nonprofit working on behalf of the 31 million Americans with kidney disease, the American Kidney Fund is dedicated to ensuring that every kidney patient has access to health care, and that every person at risk for kidney disease is empowered to prevent it. AKF provides a complete spectrum of programs and services: prevention outreach, top-rated health educational resources, and direct financial assistance enabling 1 in 5 U.S. dialysis patients to access lifesaving medical care, including dialysis and transplantation.
Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company's approach centers on its pipeline featuring clinical-stage assets targeting rare diseases with significant unmet medical needs, including sparsentan for focal segmental glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease, and RE-024 for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood. Research exploring the potential of early-stage assets in several rare diseases is also underway. Retrophin's R&D efforts are supported by revenues from the Company's commercial products Thiola®, Cholbam® and Chenodal®. For more information, please visit Retrophin.com